Elevated Expression of ADAM10 Induced by HPV E6 Influences the Prognosis of Cervical Cancer.

IF 1.1 4区生物学 Q4 GENETICS & HEREDITY

Genetic testing and molecular biomarkers Pub Date : 2023-05-01 DOI:10.1089/gtmb.2022.0170

Xuewang Guo, Yu Dou, Shuiqingqing Liu, Yue Du, Ruimeng Guo, Yingying Yue, Yu Xu, Xueying Liu, Yanying Xu

{"title":"Elevated Expression of ADAM10 Induced by HPV E6 Influences the Prognosis of Cervical Cancer.","authors":"Xuewang Guo, Yu Dou, Shuiqingqing Liu, Yue Du, Ruimeng Guo, Yingying Yue, Yu Xu, Xueying Liu, Yanying Xu","doi":"10.1089/gtmb.2022.0170","DOIUrl":null,"url":null,"abstract":"Objective: To explore the abnormal expression of ADAM10, its cause, and its clinical value in the prognosis of cervical lesions. Methods: The abnormal expression of ADAM10 was explored using the Gene Expression Profiling Interactive Analysis database, and the abnormal expression in cervical lesions was verified using immunohistochemistry (IHC). The transfection effect of shRNA was evaluated using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The expression of ADAM10 in cells was analyzed using western blotting. Results: ADAM10 was highly expressed in multiple cancers. As the disease progressed, the expression of ADAM10 gradually increased (p < 0.05). Patients with higher expression of ADAM10 had poorer survival outcomes than those with lower expression levels (p < 0.05). The expression levels of ADAM10 decreased after expression levels of E6 was inhibited. Conclusion: ADAM10 is highly expressed in cervical cancer; the higher the expression levels, the worse the survival outcome. HPV E6 is the critical driver of the elevated expression of ADAM10 in cervical cancer.","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2022.0170","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: To explore the abnormal expression of ADAM10, its cause, and its clinical value in the prognosis of cervical lesions. Methods: The abnormal expression of ADAM10 was explored using the Gene Expression Profiling Interactive Analysis database, and the abnormal expression in cervical lesions was verified using immunohistochemistry (IHC). The transfection effect of shRNA was evaluated using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The expression of ADAM10 in cells was analyzed using western blotting. Results: ADAM10 was highly expressed in multiple cancers. As the disease progressed, the expression of ADAM10 gradually increased (p < 0.05). Patients with higher expression of ADAM10 had poorer survival outcomes than those with lower expression levels (p < 0.05). The expression levels of ADAM10 decreased after expression levels of E6 was inhibited. Conclusion: ADAM10 is highly expressed in cervical cancer; the higher the expression levels, the worse the survival outcome. HPV E6 is the critical driver of the elevated expression of ADAM10 in cervical cancer.

查看原文本刊更多论文

HPV E6诱导ADAM10表达升高对宫颈癌预后的影响

目的:探讨ADAM10在宫颈病变预后中的异常表达、原因及临床价值。方法:利用基因表达谱交互分析数据库探索ADAM10的异常表达，并利用免疫组织化学(IHC)验证宫颈病变中的异常表达。采用实时定量逆转录聚合酶链反应(qRT-PCR)评价shRNA转染效果。western blotting分析细胞中ADAM10的表达。结果:ADAM10在多种肿瘤中高表达。随着疾病的进展，ADAM10的表达逐渐增加(p ADAM10比表达水平较低的患者生存结果更差(p ADAM10在E6表达水平被抑制后下降)。结论:ADAM10在宫颈癌中高表达;表达水平越高，生存结果越差。HPV E6是宫颈癌中ADAM10表达升高的关键驱动因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genetic testing and molecular biomarkers 生物-遗传学

CiteScore

2.50

自引率

7.10%

发文量

审稿时长

1 months

期刊介绍： Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results. Genetic Testing and Molecular Biomarkers coverage includes: -Diagnosis across the life span- Risk assessment- Carrier detection in individuals, couples, and populations- Novel methods and new instrumentation for genetic testing- Results of molecular, biochemical, and cytogenetic testing- Genetic counseling